; (B) a statement of whether the research is or was being carried out directly by the institute, center, agency, office, or entity or by multiple institutes, centers, agencies, offices, or entities; and (C) identification of any resulting real world evidence that is or may be used for clinical research and medical care for patients with Down syndrome. (f) Authorization of appropriations (1) In general To carry out this section, there is authorized to be appropriated $90,000,000 for each of fiscal years 2025 through 2029. (2) Supplement, not supplant Funds appropriated to carry out this section shall be used to supplement, not supplant, other funds allocated by the National Institutes of Health for research and other activities relating to Down syndrome. .